Bevespi Aerosphere


glycopyrronium / formoterol fumarate dihydrate

This medicine is authorised for use in the European Union.


Bevespi Aerosphere is a medicine used in adults to relieve the symptoms of chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.

Bevespi Aerosphere is used for maintenance (regular) treatment. It contains the active substances glycopyrronium bromide and formoterol.

This EPAR was last updated on 25/09/2023

Authorisation details

Product details
Bevespi Aerosphere
Agency product number
Active substance
  • glycopyrronium
  • formoterol fumarate dihydrate
International non-proprietary name (INN) or common name
  • glycopyrronium
  • formoterol fumarate dihydrate
Therapeutic area (MeSH)
Pulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
AstraZeneca AB
Date of issue of marketing authorisation valid throughout the European Union
Contact address

AstraZeneca AB
SE-151 85 Sodertalje

Product information

15/09/2023 Bevespi Aerosphere - EMEA/H/C/004245 - R/0017

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

formoterol and glycopyrronium bromide

Therapeutic indication

Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Assessment history

How useful was this page?

Add your rating
2 ratings
1 rating
1 rating